Compare NSYS & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSYS | TVRD |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 29.1M |
| IPO Year | 1996 | N/A |
| Metric | NSYS | TVRD |
|---|---|---|
| Price | $13.81 | $3.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | 27.6K | ★ 47.1K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,371,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.01 | N/A |
| 52 Week Low | $6.50 | $2.75 |
| 52 Week High | $15.39 | $43.65 |
| Indicator | NSYS | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 56.73 | 48.65 |
| Support Level | $8.43 | $2.75 |
| Resistance Level | N/A | $3.50 |
| Average True Range (ATR) | 0.91 | 0.23 |
| MACD | -0.16 | 0.02 |
| Stochastic Oscillator | 53.10 | 55.22 |
Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical, and manufacturing services and support, including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense, and Industrial markets, with key revenue coming from medical-related markets.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.